Stay updated with breaking news from Ross maltz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A single-center retrospective study is offering clinicians insight into the effects of biosimilar infliximab use on weight, height, and BMI trajectories in pediatric patients with inflammatory bowel disease. ....
The biosimilars month in review highlights infliximab biosimilars data presented at Digestive Disease Week (DDW) 2023, California’s proposed plan to produce and market biosimilar insulin at production-equivalent prices, and new FDA approvals. ....
No statically significant differences in ESR, CRP, TNF levels, and albumin were observed pre- and post-switch from the infliximab originator to the biosimilar. ....
Clinical outcomes of lab values were not statistically different in changes from baseline to 12 months between children with inflammatory bowel disease initiated on the TNF originator or biosimilar. ....
The biosimilars month in review highlights the positive safety and efficacy data of 3 biosimilars used to treat rheumatic diseases, gastroenterologists discuss the risks and benefits of prescribing biosimilars to their patients, and physicians emphasize the importance of patient education. ....